VEGF and metalloproteinase 2 (MMP 2) expression in gastric cancer tissue

Medical Science Monitor

Volumn 18, Issue 4, 2012, Pages

  Partyka, Robert ^a   Gonciarz, Maciej ^b   Jałowiecki, Przemysław ^a   Kokocińska, Danuta ^a   Byrczek, Tomasz ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b St Barbara Memorial Hospital   (Poland)

Author keywords

Gastric cancer; Gene expression; MMP 2; VEGF

Indexed keywords

GELATINASE A; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER INFILTRATION; CANCER PATIENT; CANCER SURGERY; CANCER TISSUE; CONTROLLED STUDY; FEMALE; GASTRECTOMY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; STOMACH CANCER;

EID: 84859555805     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.882614     Document Type: Article

References (31)

1. Szczeklik A: Choroby wewne{ogonek}trzne. [In:] Zatoński WA, Didkowska J, Olszewski W (ed.). Epidemiologia nowotworów i badania przesiewowe. Kraków, 2005; II: 1983 [in Polish]
2. Gonzalez CA, Sala N, Capella G: Genetic susceptibility and gastrin cancer risk. Int J Cancer, 2002; 100: 249-60
3. Hemminki K, Jiang Y: Familial and second gastric carcinomas: a nationwide epidemiologic study from Sweden. Cancer, 2002; 94: 1157-65
4. Howson CP, Hiyama T, Wynder EL: The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiology, 1986; 8: 1-27
5. Chomczyński P, Sacchi N: Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem, 1987; 162: 156-59
6. Chomczyński P: A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cells and tissue samples. BioTechniques, 1993; 15: 532-37
7. Szala S, Radzikowski C: Podłoże molekularne angiogenezy nowotworów. Nowotwory, 1997; 47: 1-19 [in Polish]
8. Zhang Y, Li M, Yao Q, Chen C: Recent advances in tumor hypoxia: Tumor progression, molecular mechanisms, and therapeutic implications. Med Sci Monit, 2007; 13(10): RA175-80
9. Nam SY, Ko YS, Jung J et al: A hypoxia-dependent upregulation of hypoxia- inducible factor-1 by nuclear factor-kB promotes gastric tumour growth and angiogenesis. Br J Cancer, 2011; 104(1): 166-74
10. Zielonka T: Angiogeneza - Cze{ogonek}ść I. Mechanizmy powstawania naczyń krwionośnych. Aler Ast Imm, 2003; 8(4): 169-74 [in Polish]
11. Maeda K, Chung YS, Takatsuka S et al: Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol, 1995; 13: 477-81
12. Fuhrmann-Benzakein E, Ma MN, Rubia-Brandt L et al: Elavated levels of angiogenic cytokines in the plasma of cancer patients. Int J Cancer, 2000; 85: 40-45
13. Benoy I, Salgado R, Colpaert C et al: Serum interleukin 6, plasma VEGF, serum VEGF and VEGF platelet load in breast cancer patients. Clin Breast Cancer, 2002; 2: 311-15
14. Cascinu S, Staccioli M, Gasparini G: Expression of Vascular Endothelial Growth Factor can predict even-free survival in stage II colon cancer. Clinical Cancer Research, 2000; 6: 2803-7
15. Jezierska A, Motyl T: Matrix Metalloproteinase-2 involvement in breast cancer progression: A mini-review. Med Sci Monit, 2009; 15(2): RA32-40
16. Ferrara N, Gerber HP, Lecuter J: The biology of VEGF and its receptors. Nat Med, 2003; 9: 669-75
17. Metges JP, Funderila C, Doncet L et al: Angiogenesis and p53 status in gastric cancer, prospective serum and immunohistochemical study. Ann Oncol, 2000; 11(4): 64-65
18. Jośko J, Gwoźdź B, Jedrzejowska-Szypułka H et al: Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit, 2000; 6(5): 1047-52
19. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol, 2005; 23: 10011-27
20. Ma ZL, Deng H: Research development of VEGF and its effect on angiogenesis in tumour. Jiangsu Yixue Zazhi, 2004; 30: 50-51
21. Ponta H, Hoffman M, Herlisch P: Recent advances in genetics of metastasis. Eur J Cancer, 1994; 30: 1195-2001
22. D'Amore PA, Shima DT: Tumor angiogenesis a physiological process or genetically determined? Cancer Metastasis Rev, 1996; 15: 205-12
23. Zhou Y, Li G, Wu J et al: Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. Tumour Biol, 2010; 31(6): 549-58
24. Mrena J, Wihstey JP, Nordling S: MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol, 2006; 59(6): 618-23
25. Whatling C, McPheat W, Camejo EH: Matrix Management Assigning different roles for MMP-2 and MMP-9 in Vascular Remodeling. Arter Thromb Vasc Biol, 2004; 24: 10-11
26. Lee LY, Wu CM, Wang CC et al: Expression of matrix metalloproteinases MMP-2 and MMP-9 in gastric cancer and their relation to clandin-4 expression. Histol Histopatol, 2008; 23(5): 515-21
27. Bae JH, Park MJ, Yoon SH et al: Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, akt and Sp1. Cancer Res, 2006; 66(10): 4991-95
28. Wang LB, Jiang ZN, Fan MY et al: Changes of histology and expression of MMP-2 and nm23-H1 in primary and metastatic gastric cancer. World J Gastroenterol, 2008; 14(10): 1612-16
29. Feng Ji, Chen YL, Jin WL et al: Relationship between matrix metalloproteinase- 2 mRNA expression and clinicopathological and urokinasetype plasminogen activator system parameters and prognosis in human gastric cancer. World J Gastroenterol, 2005; 11(21): 3222-26
30. Cai H, Kong ZR, Chen HM: Matrix metalloproteinase-2 and angiogenesis in gastric cancer. Aizheng, 2002; 21: 25-28
31. Descheemacker KA, Wyns S, Nelles L et al: Interaction of AP-1, AP-2 and Sp-1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response. J Biol Chem, 1992; 267: 15086-91